Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

Eliana Amato, Marco Dal Molin, Andrea Mafficini, Jun Yu, Giuseppe Malleo, Borislav Rusev, Matteo Fassan, Davide Antonello, Yoshihiko Sadakari, Paola Castelli, Giuseppe Zamboni, Anirban Maitra, Roberto Salvia, Ralph H. Hruban, Claudio Bassi, Paola Capelli, Rita T. Lawlor, Michael Goggins, Aldo Scarpa

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty-two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer-associated genes, using ion torrent semiconductor-based next-generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN-associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92%) of IPMNs. GNAS was mutated in 38/48 (79%) IPMNs, KRAS in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low-frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10% and 6%) were only observed in high-grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN-associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN-associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next-generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms.

Original languageEnglish
Pages (from-to)217-227
Number of pages11
JournalJournal of Pathology
Volume233
Issue number3
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

Fingerprint

Neoplasm Genes
Pancreatic Neoplasms
Neoplasms
Mutation
Cyst Fluid
Carcinoma
Genes
High-Throughput Nucleotide Sequencing
Semiconductors
p53 Genes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. / Amato, Eliana; Molin, Marco Dal; Mafficini, Andrea; Yu, Jun; Malleo, Giuseppe; Rusev, Borislav; Fassan, Matteo; Antonello, Davide; Sadakari, Yoshihiko; Castelli, Paola; Zamboni, Giuseppe; Maitra, Anirban; Salvia, Roberto; Hruban, Ralph H.; Bassi, Claudio; Capelli, Paola; Lawlor, Rita T.; Goggins, Michael; Scarpa, Aldo.

In: Journal of Pathology, Vol. 233, No. 3, 01.01.2014, p. 217-227.

Research output: Contribution to journalArticle

Amato, E, Molin, MD, Mafficini, A, Yu, J, Malleo, G, Rusev, B, Fassan, M, Antonello, D, Sadakari, Y, Castelli, P, Zamboni, G, Maitra, A, Salvia, R, Hruban, RH, Bassi, C, Capelli, P, Lawlor, RT, Goggins, M & Scarpa, A 2014, 'Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas', Journal of Pathology, vol. 233, no. 3, pp. 217-227. https://doi.org/10.1002/path.4344
Amato, Eliana ; Molin, Marco Dal ; Mafficini, Andrea ; Yu, Jun ; Malleo, Giuseppe ; Rusev, Borislav ; Fassan, Matteo ; Antonello, Davide ; Sadakari, Yoshihiko ; Castelli, Paola ; Zamboni, Giuseppe ; Maitra, Anirban ; Salvia, Roberto ; Hruban, Ralph H. ; Bassi, Claudio ; Capelli, Paola ; Lawlor, Rita T. ; Goggins, Michael ; Scarpa, Aldo. / Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. In: Journal of Pathology. 2014 ; Vol. 233, No. 3. pp. 217-227.
@article{5f24b3b0c17649d3a86ac5d741179391,
title = "Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas",
abstract = "Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty-two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer-associated genes, using ion torrent semiconductor-based next-generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN-associated carcinomas. At least one somatic mutation was observed in 46/48 (96{\%}) IPMNs; 29 (60{\%}) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92{\%}) of IPMNs. GNAS was mutated in 38/48 (79{\%}) IPMNs, KRAS in 24/48 (50{\%}) and these mutations coexisted in 18/48 (37.5{\%}) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low-frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10{\%} and 6{\%}) were only observed in high-grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN-associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN-associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next-generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms.",
author = "Eliana Amato and Molin, {Marco Dal} and Andrea Mafficini and Jun Yu and Giuseppe Malleo and Borislav Rusev and Matteo Fassan and Davide Antonello and Yoshihiko Sadakari and Paola Castelli and Giuseppe Zamboni and Anirban Maitra and Roberto Salvia and Hruban, {Ralph H.} and Claudio Bassi and Paola Capelli and Lawlor, {Rita T.} and Michael Goggins and Aldo Scarpa",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/path.4344",
language = "English",
volume = "233",
pages = "217--227",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

AU - Amato, Eliana

AU - Molin, Marco Dal

AU - Mafficini, Andrea

AU - Yu, Jun

AU - Malleo, Giuseppe

AU - Rusev, Borislav

AU - Fassan, Matteo

AU - Antonello, Davide

AU - Sadakari, Yoshihiko

AU - Castelli, Paola

AU - Zamboni, Giuseppe

AU - Maitra, Anirban

AU - Salvia, Roberto

AU - Hruban, Ralph H.

AU - Bassi, Claudio

AU - Capelli, Paola

AU - Lawlor, Rita T.

AU - Goggins, Michael

AU - Scarpa, Aldo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty-two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer-associated genes, using ion torrent semiconductor-based next-generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN-associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92%) of IPMNs. GNAS was mutated in 38/48 (79%) IPMNs, KRAS in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low-frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10% and 6%) were only observed in high-grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN-associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN-associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next-generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms.

AB - Intraductal neoplasms are important precursors to invasive pancreatic cancer and provide an opportunity to detect and treat pancreatic neoplasia before an invasive carcinoma develops. The diagnostic evaluation of these lesions is challenging, as diagnostic imaging and cytological sampling do not provide accurate information on lesion classification, the grade of dysplasia or the presence of invasion. Moreover, the molecular driver gene mutations of these precursor lesions have yet to be fully characterized. Fifty-two intraductal papillary neoplasms, including 48 intraductal papillary mucinous neoplasms (IPMNs) and four intraductal tubulopapillary neoplasms (ITPNs), were subjected to the mutation assessment in 51 cancer-associated genes, using ion torrent semiconductor-based next-generation sequencing. P16 and Smad4 immunohistochemistry was performed on 34 IPMNs and 17 IPMN-associated carcinomas. At least one somatic mutation was observed in 46/48 (96%) IPMNs; 29 (60%) had multiple gene alterations. GNAS and/or KRAS mutations were found in 44/48 (92%) of IPMNs. GNAS was mutated in 38/48 (79%) IPMNs, KRAS in 24/48 (50%) and these mutations coexisted in 18/48 (37.5%) of IPMNs. RNF43 was the third most commonly mutated gene and was always associated with GNAS and/or KRAS mutations, as were virtually all the low-frequency mutations found in other genes. Mutations in TP53 and BRAF genes (10% and 6%) were only observed in high-grade IPMNs. P16 was lost in 7/34 IPMNs and 9/17 IPMN-associated carcinomas; Smad4 was lost in 1/34 IPMNs and 5/17 IPMN-associated carcinomas. In contrast to IPMNs, only one of four ITPNs had detectable driver gene (GNAS and NRAS) mutations. Deep sequencing DNA from seven cyst fluid aspirates identified 10 of the 13 mutations detected in their associated IPMN. Using next-generation sequencing to detect cyst fluid mutations has the potential to improve the diagnostic and prognostic stratification of pancreatic cystic neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=84902345151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902345151&partnerID=8YFLogxK

U2 - 10.1002/path.4344

DO - 10.1002/path.4344

M3 - Article

VL - 233

SP - 217

EP - 227

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 3

ER -